Amicus Therapeutics, Inc. (NASDAQ:FOLD) Holdings Cut by BNP Paribas Financial Markets

BNP Paribas Financial Markets lowered its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 14.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 484,560 shares of the biopharmaceutical company's stock after selling 81,416 shares during the quarter. BNP Paribas Financial Markets owned about 0.16% of Amicus Therapeutics worth $4,565,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the company. Wellington Management Group LLP boosted its holdings in shares of Amicus Therapeutics by 18.8% in the fourth quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company's stock valued at $268,112,000 after acquiring an additional 4,497,950 shares in the last quarter. Norges Bank bought a new position in shares of Amicus Therapeutics in the fourth quarter valued at approximately $29,033,000. Rock Springs Capital Management LP boosted its holdings in shares of Amicus Therapeutics by 107.9% in the fourth quarter. Rock Springs Capital Management LP now owns 2,599,425 shares of the biopharmaceutical company's stock valued at $24,487,000 after acquiring an additional 1,349,145 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Amicus Therapeutics by 174.1% in the fourth quarter. Renaissance Technologies LLC now owns 2,108,616 shares of the biopharmaceutical company's stock valued at $19,863,000 after acquiring an additional 1,339,316 shares in the last quarter. Finally, Trexquant Investment LP boosted its holdings in Amicus Therapeutics by 101.6% during the fourth quarter. Trexquant Investment LP now owns 966,049 shares of the biopharmaceutical company's stock worth $9,100,000 after buying an additional 486,827 shares in the last quarter.

Amicus Therapeutics Trading Down 0.2%

Amicus Therapeutics stock traded down $0.01 during midday trading on Monday, reaching $6.42. The stock had a trading volume of 5,792,808 shares, compared to its average volume of 2,823,780. The firm's fifty day simple moving average is $7.32 and its two-hundred day simple moving average is $8.85. Amicus Therapeutics, Inc. has a twelve month low of $5.81 and a twelve month high of $12.65. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The firm has a market cap of $1.98 billion, a price-to-earnings ratio of -35.67, a PEG ratio of 1.51 and a beta of 0.64.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on FOLD shares. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. StockNews.com cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Monday, May 5th. UBS Group raised their target price on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Wells Fargo & Company reduced their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, February 20th. Finally, The Goldman Sachs Group reduced their target price on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a report on Friday, May 2nd. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $16.22.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.